Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 14.67
CEMP's Cash to Debt is ranked lower than
56% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 83.29 vs. CEMP: 14.67 )
Ranked among companies with meaningful Cash to Debt only.
CEMP' s Cash to Debt Range Over the Past 10 Years
Min: 1.12  Med: 8.16 Max: No Debt
Current: 14.67
Equity to Asset 0.82
CEMP's Equity to Asset is ranked higher than
67% of the 711 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CEMP: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
CEMP' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.75 Max: 0.82
Current: 0.82
0.48
0.82
F-Score: 4
Z-Score: 2.62
M-Score: -1.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -672.95
CEMP's Operating margin (%) is ranked lower than
74% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -81.51 vs. CEMP: -672.95 )
Ranked among companies with meaningful Operating margin (%) only.
CEMP' s Operating margin (%) Range Over the Past 10 Years
Min: -672.95  Med: -390.38 Max: -325.59
Current: -672.95
-672.95
-325.59
Net-margin (%) -678.68
CEMP's Net-margin (%) is ranked lower than
74% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. CEMP: -678.68 )
Ranked among companies with meaningful Net-margin (%) only.
CEMP' s Net-margin (%) Range Over the Past 10 Years
Min: -678.68  Med: -405.16 Max: -333.64
Current: -678.68
-678.68
-333.64
ROE (%) -62.91
CEMP's ROE (%) is ranked lower than
67% of the 875 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. CEMP: -62.91 )
Ranked among companies with meaningful ROE (%) only.
CEMP' s ROE (%) Range Over the Past 10 Years
Min: -101.98  Med: -94.12 Max: -62.91
Current: -62.91
-101.98
-62.91
ROA (%) -49.46
CEMP's ROA (%) is ranked lower than
67% of the 967 Companies
in the Global Biotechnology industry.

( Industry Median: -29.03 vs. CEMP: -49.46 )
Ranked among companies with meaningful ROA (%) only.
CEMP' s ROA (%) Range Over the Past 10 Years
Min: -191.64  Med: -64.24 Max: -49.46
Current: -49.46
-191.64
-49.46
ROC (Joel Greenblatt) (%) -133712.31
CEMP's ROC (Joel Greenblatt) (%) is ranked lower than
98% of the 927 Companies
in the Global Biotechnology industry.

( Industry Median: -368.19 vs. CEMP: -133712.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CEMP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -133712.31  Med: -41875.95 Max: -18139.82
Current: -133712.31
-133712.31
-18139.82
EBITDA Growth (3Y)(%) 21.20
CEMP's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CEMP: 21.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CEMP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -67.7  Med: -65.2 Max: 21.2
Current: 21.2
-67.7
21.2
EPS Growth (3Y)(%) 19.30
CEMP's EPS Growth (3Y)(%) is ranked higher than
75% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CEMP: 19.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CEMP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.3  Med: -67.2 Max: 19.3
Current: 19.3
-69.3
19.3
» CEMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CEMP Guru Trades in Q3 2015

Paul Tudor Jones Sold Out
» More
Q1 2016

CEMP Guru Trades in Q1 2016

Jim Simons 30,330 sh (New)
George Soros 181,825 sh (New)
» More
Q2 2016

CEMP Guru Trades in Q2 2016

Jim Simons 205,300 sh (+576.89%)
George Soros Sold Out
» More
Q3 2016

CEMP Guru Trades in Q3 2016

Mario Gabelli 53,400 sh (New)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CEMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:MESO, NAS:CRBP, NAS:SRNE, NAS:AKBA, NAS:SPPI, NAS:FOMX, NAS:SVA, NAS:ADAP, NAS:GERN, NAS:NVAX, NAS:OMED, NAS:LJPC, NAS:BSTC, NAS:SYRS, NAS:EDGE, OTCPK:TYMI, NAS:CRVS, NAS:IMMU, NAS:TRVN, NAS:CGEN » details
Traded in other countries:9C1.Germany,
Cempra Inc is a clinical-stage pharmaceutical company. It develops antibiotics for acute care & community settings to meet critical medical needs in treatment of bacterial infectious diseases, respiratory tract & chronic staphylococcal infections.

Cempra Inc is the successor entity of Cempra Pharmaceuticals, Inc. which was incorporated on November 18, 2005 and commenced operations in January 2006. The Company is a clinical-stage pharmaceutical company which is engaged in the development of differentiated antibiotics for the acute care and community settings to meet critical medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company's main product, solithromycin (CEM-101), is in Phase 3 clinical trials. The Company is developing solithromycin in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP. Solithromycin is a potent new fourth generation macrolide and the first fluoroketolide in clinical development. The Company is also completed a Phase 2 study of solithromycin in uncomplicated gonorrhea. Its second program is Taksta, which the Company is developing in the U.S. as a long term oral treatment for prosthetic joint infections caused by staphylococci, including S. aureus and MRSA. The Company is conducting a Phase 2 trial for Taksta in patients with prosthetic joint infections and have submitted a proposal for a Phase 3 trial for Tasksta as a treatment for PJI. The Company has licensed solithromycin to Toyama Chemical Co., Ltd. for development and commercialization in Japan while retaining the rights to the rest of the world. The Company is developing Taksta in the U.S. as a long term oral treatment of prosthetic joint infections, or PJI, caused by staphylococci, including S. aureus and methicillin-resistant Staphylococcus aureus, or MRSA.

Ratios

vs
industry
vs
history
P/B 1.90
CEMP's P/B is ranked higher than
80% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: 3.57 vs. CEMP: 1.90 )
Ranked among companies with meaningful P/B only.
CEMP' s P/B Range Over the Past 10 Years
Min: 1.65  Med: 6.79 Max: 20.33
Current: 1.9
1.65
20.33
P/S 22.54
CEMP's P/S is ranked lower than
59% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 12.03 vs. CEMP: 22.54 )
Ranked among companies with meaningful P/S only.
CEMP' s P/S Range Over the Past 10 Years
Min: 19.55  Med: 47.59 Max: 76.39
Current: 22.54
19.55
76.39
Current Ratio 10.18
CEMP's Current Ratio is ranked higher than
77% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CEMP: 10.18 )
Ranked among companies with meaningful Current Ratio only.
CEMP' s Current Ratio Range Over the Past 10 Years
Min: 2.48  Med: 10.18 Max: 30.34
Current: 10.18
2.48
30.34
Quick Ratio 10.18
CEMP's Quick Ratio is ranked higher than
78% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. CEMP: 10.18 )
Ranked among companies with meaningful Quick Ratio only.
CEMP' s Quick Ratio Range Over the Past 10 Years
Min: 2.48  Med: 10.18 Max: 30.34
Current: 10.18
2.48
30.34
Days Sales Outstanding 104.24
CEMP's Days Sales Outstanding is ranked lower than
74% of the 595 Companies
in the Global Biotechnology industry.

( Industry Median: 63.02 vs. CEMP: 104.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
CEMP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.37  Med: 75.96 Max: 104.24
Current: 104.24
56.37
104.24

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -20.90
CEMP's 3-Year Average Share Buyback Ratio is ranked lower than
69% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. CEMP: -20.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CEMP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -314.5  Med: -288.6 Max: -20.9
Current: -20.9
-314.5
-20.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.96
CEMP's Price/Net Cash is ranked higher than
91% of the 875 Companies
in the Global Biotechnology industry.

( Industry Median: 6.19 vs. CEMP: 1.96 )
Ranked among companies with meaningful Price/Net Cash only.
CEMP' s Price/Net Cash Range Over the Past 10 Years
Min: 1.96  Med: 6.1 Max: 16.1
Current: 1.96
1.96
16.1
Price/Net Current Asset Value 1.91
CEMP's Price/Net Current Asset Value is ranked higher than
90% of the 1006 Companies
in the Global Biotechnology industry.

( Industry Median: 5.65 vs. CEMP: 1.91 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CEMP' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.91  Med: 5.93 Max: 14.51
Current: 1.91
1.91
14.51
Price/Tangible Book 1.90
CEMP's Price/Tangible Book is ranked higher than
85% of the 1150 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CEMP: 1.90 )
Ranked among companies with meaningful Price/Tangible Book only.
CEMP' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.9  Med: 5.88 Max: 14.43
Current: 1.9
1.9
14.43
Price/Median PS Value 0.47
CEMP's Price/Median PS Value is ranked higher than
87% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CEMP: 0.47 )
Ranked among companies with meaningful Price/Median PS Value only.
CEMP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.47  Med: 1.02 Max: 1.52
Current: 0.47
0.47
1.52
Earnings Yield (Greenblatt) (%) -64.50
CEMP's Earnings Yield (Greenblatt) (%) is ranked lower than
71% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: -8.00 vs. CEMP: -64.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CEMP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -92.79  Med: 0 Max: 0
Current: -64.5
-92.79
0

More Statistics

Revenue (TTM) (Mil) $15.87
EPS (TTM) $ -2.22
Beta1.67
Short Percentage of Float22.16%
52-Week Range $5.70 - 33.15
Shares Outstanding (Mil)52.38

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 14 26 107 187
EPS ($) -2.51 -2.35 -1.40 0.48
EPS w/o NRI ($) -2.51 -2.35 -1.40 0.48
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CEMP

Headlines

Articles On GuruFocus.com
Does Cempra Have The Next Blockbuster Drug? Jan 08 2015 

More From Other Websites
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Cempra, Inc. and... Dec 02 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in... Dec 02 2016
SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Cempra, Inc.... Dec 01 2016
Wolf Haldenstein Adler Freeman & Herz LLP Reminds Cempra, Inc, Investors That A Securities Class Has... Dec 01 2016
Why These 3 Healthcare Stocks Lost Half Their Value in November Dec 01 2016
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Cempra, Inc. and... Dec 01 2016
Lifshitz & Miller Law Firm Announces Investigation of Adeptus Health Inc., Avid Technology, Inc.,... Dec 01 2016
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Dec 01 2016
Rosen Law Firm Reminds Cempra, Inc. Investors of Important Deadline in Class Action - CEMP Nov 30 2016
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Cempra, Inc. and... Nov 30 2016
EXPANDED CLASS PERIOD: Levi & Korsinsky, LLP Notifies Shareholders of Cempra, Inc. of a Class Action... Nov 30 2016
CEMPRA INC. INVESTOR ALERT: Hagens Berman Alerts Cempra Investors to Expanded Class Period and Lead... Nov 30 2016
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Cempra, Inc. and... Nov 28 2016
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Nov 28 2016
EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Cempra, Inc. and... Nov 28 2016
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Nov 28 2016
CEMPRA INC. INVESTOR REMINDER: Hagens Berman Reminds Cempra Inc. Investors of Investigation into... Nov 28 2016
SHAREHOLDER ALERT: CLASS PERIOD EXPANED IN CLASS ACTION LAWSUIT – Brower Piven Encourages... Nov 27 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in... Nov 25 2016
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Cempra, Inc. and... Nov 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)